Splicing factor mutations (SRSF2, SF3B1, U2AF1) are more heavily enriched in TP53 mutant MDS that evolves to AML, suggesting a trajectory where splicing mutations occur first followed by TP53 disruption during disease progression [67]. This evidence concerns the gene TP53 and acute myeloid leukemia.